title: Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.
abstract: BACKGROUND
  CML includes 30% of all leukemias, and occurs from childhood to old age. The present study was a retrospective analysis of chronic phase CML patients registered to a Hematology Clinic in Kermanshah, Iran, with checking of treatment options.
  
  
  METHODS
  Between 2002 and 2014, 85 CML patients referred to our hematology clinic were enrolled in our study. We surveyed age, sex, B-symptoms, splenomegaly, Sokal score, Hasford score, treatment and survival in all patients. Philadelphia chromosome analysis was conducted for each patient by conventional cytogenetics. We compared treatment in the patients with three drugs, imatinib, hydroxyurea (HU) and interferon alpha (IFN-α).
  
  
  RESULTS
  The mean age of the patients at diagnosis was 47.5 ± 14.5 years (range, 23-82 years), with 43 (50.6%) being male. Some 13 (15.3%) were referred to our clinic for the first time with B-symptoms and 44 patients (51.8%) had splenomegaly. The Sokal score for 77 (90.6%) was low, 4 (4.7%) was intermediate and 4(4.7%) was high, but Hasford (Euro) scores for all patients were low. The 5-year survival rate for treated patients with imatinib, imatinib plus HU and imatinib plus HU plus IFN-α was 90.5%, 81.1% and 55.6%, respectively
  
  
  CONCLUSIONS
  The results show that imatinib therapy alone provides better survival in CML patients compared to HU or IFN-α. Combinations of IFN-α and/or HU with imatinib probably reduce survival.
authors.affiliation: Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran E-mail : sadeghi_mbrc@yahoo.com.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Payandeh
authors.forename: Masoud
authors.initials: M
authors.lastname: Sadeghi
authors.forename: Edris
authors.initials: E
authors.lastname: Sadeghi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D007492:Iran; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013163:Splenomegaly / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D000068877:Imatinib Mesylate; D006918:Hydroxyurea